Clinuvel Pharmaceuticals Ltd has released a press release.
Appendix 4E and Annual Report to Shareholders 2025
Filed with ASX ·
Watch Clinuvel Pharmaceuticals' latest callClinuvel Pharmaceuticals (ASX:CUV) Q4 2026 Earnings Call · Replay · Aug 27Read the transcript of Clinuvel Pharmaceuticals (ASX:CUV) Q4 2026 Earnings Call6ix hasn’t read this filing yet.
Clinuvel Pharmaceuticals Limited on 6ix
In the deck
Story so far
Earlier from Clinuvel Pharmaceuticals
- CLINUVEL preparing upgrade of ADR program to Level II, Nasdaq uplist
- CLINUVEL preparing upgrade of ADR program, NASDAQ uplist
- Study confirms NB-UVB needed to activate repigmentation
- CLINUVEL management update
- CLINUVEL recruits 200 patients in Phase III vitiligo trial CUV105
Later from Clinuvel Pharmaceuticals
- CLINUVEL delivers ninth consecutive revenues growth & profit
- Investor Presentation
- SCENESSE efficacy in vitiligo - new cases presented to EADV
- EMA approves year-round SCENESSE treatment
- CLINUVEL to advance novel pharmaceutical formulations in preclinical program
Follow Clinuvel Pharmaceuticals into a list and get an email when it puts out news.
Follow Clinuvel Pharmaceuticals